Clinical trial · Observational
Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care
Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care (INTERCEPTioN for Suspected Lung Cancer)for Suspected Lung Cancer)
NCT06482073CI-TRIAL-00123822recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 9, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260909-000002
Summary
Brief summary (as posted)
This study evaluates the effectiveness of tumor samples in providing information about hereditary or cancer specific genetic variants that may have a role in diagnosis of cancer and to develop genetic results and medical record databank for future studies.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Carcinoma | Lung Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Metastatic Malignant Neoplasm in the Lung | Lung Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-Interventional Study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational
- description
- Patients receive genomic counseling and genomic testing education, undergo blood or saliva collection, provide previously collected tissue sample and have medical records reviewed on study. Patients and healthcare providers receive results of any genetic variants found on testing.
- interventionNames
- Other: Non-Interventional Study
Primary outcomes (1)
- measure
- Percent of samples adequate for sequencing
- timeFrame
- Up to 2 years
- description
- Assessed based on the number of tissue samples determined to be adequate for WES (Whole Exome Sequencing)/WT (wild-type) sequencing.
Secondary outcomes (1)
- measure
- Data bank of genomic data
- timeFrame
- Up to 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subject age 18 years and older * Subject is scheduled/was scheduled for a bronchoscopy or surgical resection as part of standard of care * Subject with a moderate to high risk of lung cancer based on clinical demographic and radiologic information or with suspected metastatic disease * Ability to provide blood or saliva sample * Ability to provide archived tissue * Subject is able to understand and adhere to study requirements and able to provide informed consent Exclusion Criteria: * Individuals who have situations that would limit compliance with the study requirements * Institutionalized (i.e. federal medical prison) * Pregnant * Prior germline genetic testing with a 40+ multi-gene panel AND/OR prior somatic tissue (250+ gene) testing utilizing the tissue from the bronchoscopy or surgical resection
References
Publications (0)
Data not yet available
No reference posted for this study.